Private health market: the Competition Commission makes another controversial decision
The Competition Commission, in its provisional findings published last summer, found several structural and conduct features in the private healthcare market that gave rise to adverse effects on competition. It found, for example, that there were high barriers to entry for full-service hospitals and that there were weak competitive constraints in a certain local markets. The Competition Commission had provisionally concluded that these features were likely to lead to higher prices for patients.
Indeed, the Competition Commission concluded that its ‘initial estimate of the detriment caused by the market power of HCA, BMI and Spire is between £173m and £193m a year between 2009 and 2011’. The hospital operators contest that they exercise market power or make excess profits at the expense of patients.
This month, it has published its provisional decision on remedies arising from its private healthcare market investigation…
If you are registered and logged in to the site, click on the link below to read the rest of the Wragge & Co briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
£27m award for delays to generic capsules launch is upheld.
Also; significant rises in the Annual Tax on Enveloped Dwellings.